Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug resistance, and cell growth in A549 human lung cancer cells

Chinese Medicine (United Kingdom)

Volumn 7, Issue , 2012, Pages

  He, Chengwei ^a,b,c   Rong, Rong ^a,d   Liu, Jing ^a   Wan, Jianbo ^b,c   Zhou, Keyuan ^e   Kang, Jing X ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MACAU   (Macao)

^c University of Macau   (Macao)

^d THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^e GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BERBERINE; CAMPTOTHECIN; COPTIS EXTRACT; DICHLOROFLUORESCEIN; FLUOROURACIL; HERBACEOUS AGENT; PACLITAXEL; REACTIVE OXYGEN METABOLITE; RHODAMINE 123; TETRAZOLIUM; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; COPTIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; OXIDATION;

EID: 84862224423     PISSN: None     EISSN: 17498546     Source Type: Journal    
DOI: 10.1186/1749-8546-7-11     Document Type: Article

References (30)

1. Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008, 8:99-111. 10.2174/187153008784534330, 2467395, 18537696.
2. Chang YC, Chen LY. Determination of berberine in coptis. Yao Xue Xue Bao 1962, 13:418-423.
3. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol 2009, 126:5-17. 10.1016/j.jep.2009.08.009, 19686830.
4. Iizuka N, Miyamoto K, Okita K, Tangoku A, Hayashi H, Yosino S, Abe T, Morioka T, Hazama S, Oka M. Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Lett 2000, 148:19-25. 10.1016/S0304-3835(99)00264-5, 10680588.
5. Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y, Wang W, Xie C, Meng J, Wang L, Wu B, Liu S, Tian D, Zhu F, He Z, Deng F, Cao Y. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8 F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine. J Biol Chem 2009, 284:27456-27466. 10.1074/jbc.M109.033795, 2785675, 19651779.
6. Jantova S, Cipak L, Cernakova M, Kost'alova D. Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells. J Pharm Pharmacol 2003, 55:1143-1149.
7. Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem 2010, 111:1426-1436. 10.1002/jcb.22869, 20830746.
8. Soule HD, Vazquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer I 1973, 51(5):1409-1416.
9. Kang JX, Liu J, Wang J, He C, Li FP. The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-beta and TNF-alpha in human breast cancer cells. Carcinogenesis 2005, 26:1934-1939. 10.1093/carcin/bgi154, 15958519.
10. Liu J, He C, Zhou K, Wang J, Kang JX. Coptis extracts enhance the anticancer effect of estrogen receptor antagonists on human breast cancer cells. Biochem Biophys Res Commun 2009, 378:174-178. 10.1016/j.bbrc.2008.10.169, 3454467, 19000652.
11. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. J Am Med Assoc 2004, 292:470-484.
12. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000, 5:415-418. 10.1023/A:1009616228304, 11256882.
13. Gallego MA, Ballot C, Kluza J, Hajji N, Martoriati A, Castera L, Cuevas C, Formstecher P, Joseph B, Kroemer G, Bailly C, Marchetti P. Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway. Oncogene 2008, 27:1981-1992. 10.1038/sj.onc.1210833, 17906690.
14. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001, 7:1798-1804.
15. Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Brit Med J 1995, 311:899-909. Cancer Collaborative Group.
16. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784. 10.1200/JCO.2004.08.001, 14990632.
17. Brown JR, DuBois RN. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 2004, 10:4266s-4269s. 10.1158/1078-0432.CCR-040014, 15217972.
18. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP. In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer I 1973, 51(5):1417-1423.
19. Fontaine M, Elmquist WF, Miller DW. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci 1996, 59:1521-1531. 10.1016/0024-3205(96)00483-3, 8890933.
20. Brouty-Boye D, Kolonias D, Wu CJ, Savaraj N, Lampidis TJ. Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux. Cancer Res 1995, 55:1633-1638.
21. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 1995, 18:775-794. 10.1016/0891-5849(94)00198-S, 7750801.
22. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004, 7:97-110. 10.1016/j.drup.2004.01.004, 15158766.
23. Hur JM, Hyun MS, Lim SY, Lee WY, Kim D. The combination of berberine and irradiation enhances anti-cancer effects via activation of p38 MAPK pathway and ROS generation in human hepatoma cells. J Cell Biochem 2009, 107:955-964. 10.1002/jcb.22198, 19492307.
24. Liu B, Wang G, Yang J, Pan X, Yang Z, Zang L. Berberine Inhibits Human Hepatoma Cell Invasion without Cytotoxicity in Healthy Hepatocytes. PLoS One 2011, 6(6):e21416. 10.1371/journal.pone.0021416, 3123339, 21738655.
25. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002, 3:420-425. 10.1093/embo-reports/kvf094, 1084107, 11991946.
26. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3(5):330-338. 10.1038/nrc1074, 12724731.
27. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AI, Sim GA. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate. J Am Chem Soc 1966, 88(16):3888-3890.
28. Wani M, Taylor H, Wall M, Coggon P, McPhail A. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971, 93(9):2325-2327. 10.1021/ja00738a045, 5553076.
29. Kim SA, Kwon Y, Kim JH, Muller MT, Chung IK. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine. Biochemistry 1998, 37:16316-16324. 10.1021/bi9810961, 9819224.
30. Lin TH, Kuo HC, Chou FP, Lu FJ. Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer 2008, 8:58. 10.1186/1471-2407-8-58, 2275285, 18294404.